114 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
21 Available A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma
Condition: Liver Cancer
Intervention: Device: Theraspheres
22 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
23 Available Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
Conditions: Graft vs Host Disease;   Graft-Versus-Host Disease
Intervention: Biological: remestemcel-L
24 Available Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody (CheckMate 168)
Condition: Stage III (Unresectable) or Stage IV Advanced Melanoma
Intervention: Drug: Nivolumab
25 Available Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Conditions: EBV Infection;   CMV Infection;   Adenoviral Infection
Intervention: Biological: Trivirus-Specific CTLs
26 Available Compassionate Use of Dolutegravir and Ibalizumab for the Treatment of HIV Infection
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Dolutegravir;   Drug: Ibalizumab
27 Available Expanded Access Study of Amifampridine Phosphate in LEMS, Congenital Myasthenic Syndrome, or Downbeat Nystagmus Patients
Conditions: Lambert-Eaton Myasthenic Syndrome;   Congenital Myasthenic Syndrome;   Downbeat Nystagmus
Intervention: Drug: Amifampridine Phosphate
28 Available An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Condition: Metastatic Breast Cancer
Intervention: Drug: Eribulin Mesylate
29 Available Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid
30 Available Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
Condition: Dravet Syndrome
Intervention: Drug: Stiripentol
31 Available Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease
Condition: Byler Disease
Intervention: Drug: RAVICTI
32 Unknown  Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
Condition: Triple Negative Local Advanced Breast Cancer
Intervention: Drug: docetaxel oxaliplatin
33 Available Treatment of Lambert-Eaton Syndrome With 3,4 DAP
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4 DAP
34 Available Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
Condition: Patient 0001-000412 Under Study P05538
Intervention: Drug: ficlatuzumab
35 Unknown  Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain
Conditions: Chronic Low Back Pain;   Acupuncture
Intervention: Device: Acupuncture, Pak-sham needle
36 Unknown  131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Condition: Neuroblastoma
Intervention: Drug: Metaiodobenzylguanidine (MIBG)
37 Unknown  Hypercalciuria and Calcium Stone Disease in Caucasian Patients
Conditions: Hypercalciuria;   Calcium Stone Disease
Interventions: Radiation: Radiological testing;   Genetic: Pediatric Urologic DNA and History Repository
38 Available Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics
Conditions: Percentage Body-Weight;   Weight-Bearing Values;   Weight-bearing Gait Characteristics
Intervention: Device: SmartStep insole
39 Available Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
40 Available 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Conditions: Carcinoid Tumors;   Islet Cell (Pancreatic NET);   Other Neuroendocrine Tumors
Intervention: Drug: 68Ga-DOTA TATE

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years